New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.)
On top of two previously announced major commercial payer agreements and Medicaid availability in most states, pharmacy coverage for TONMYA will total approximately 46% of all covered lives in the U.S.
Sales force expansion underway with additional field deployment expected by mid-third quarter 2026
BERKELEY HEIGHTS, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biotechnology company, today announced a major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.). The new agreement will go into effect on January 1, 2027. On top of two prior commercial coverage agreements with leading group purchasing organizations (GPOs) effective in the second quarter of 2026, and Medicaid availability in most states representing approximately 73 million lives, pharmacy coverage for TONMYA on January 1, 2027, will total approximately 145 million covered lives (46% of 314 million covered lives). Discussions with other commercial and Medicare payers continue to advance.
Following these coverage milestones and positive trends across the launch's key performance indicators, Tonix is executing its strategy to incrementally grow the TONMYA sales force and expects to deploy 50 new sales force representatives in the field by mid-third quarter 2026, bringing the full sales force to approximately 150 people.
"Patient access to TONMYA is accelerating with the new Medicare agreement on top of two previously announced commercial coverage wins in the first two full quarters of launch," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. "Having gained substantial patient access, we are expanding our sales force. We believe we are strongly positioned to address patients' interest in an alternative fibromyalgia medicine and realize the significant potential of the TONMYA opportunity. TONMYA is a first-in-class, non-opioid analgesic designed for daily bedtime administration and long-term use that could serve as an important treatment option."
Thomas Englese, MBA, Executive Vice President, Commercial Operations, added, "Our coverage growth reflects the recognition of TONMYA's value for patients and healthcare prescribers (HCPs). Alongside this progress, we are also seeing positive signals across our launch key metrics, including new prescribers, new patients initiating treatment, total prescriptions, and refill prescriptions. By scaling our field team, we expect to engage more top-target HCPs through increased breadth and frequency. We are simultaneously expanding marketing and medical affairs activities to develop greater understanding of fibromyalgia and TONMYA among patients and HCPs. We remain focused on operational excellence and execution."